Tag - drugmakers

 
 

DRUGMAKERS

Japan Times
JAPAN / Science & Health
Oct 15, 2022
Fujifilm gives up developing Avigan drug for COVID-19 treatment
Avigan, initially developed as a drug for influenza, emerged as a potential treatment for the coronavirus during the early stages of the pandemic.
Japan Times
WORLD / Science & Health
Apr 19, 2022
Scientists question data behind an experimental Alzheimer’s drug
Studies linked to Cassava Sciences, once a stock market favorite, have been retracted or challenged by medical journals.
Japan Times
WORLD
Dec 21, 2021
EU backs Novavax shot as region's fifth COVID-19 vaccine
It is not clear yet how Novavax performs against the omicron variant, or whether a booster dose will be needed.
Japan Times
WORLD
Nov 27, 2021
Merck says its antiviral pill is less effective in final analysis
A final analysis of a clinical trial said the antiviral pill reduced the risk of hospitalization and death among high-risk COVID patients by 30%, down from an earlier estimate of 50%.
Japan Times
ASIA PACIFIC
Nov 8, 2021
South Korea to purchase 70,000 courses of new Pfizer COVID-19 pill
Pfizer has said trial results showed that its Paxlovid pill reduced by 89% the risk of hospitalization or death in some patients.
Japan Times
WORLD / Science & Health / ANALYSIS
Nov 6, 2021
Pfizer results open door to new chapter for COVID treatments
The world needs an easy-to-take COVID-19 treatment. Pfizer Inc.u2019s and Merck & Co. Inc.u2019s new pills may be just that. But questions remain about their safety and how well they will work.
Japan Times
WORLD
Oct 30, 2021
Pfizer won the first round, but Moderna sees final victory ahead
Pfizer has been first across the finish line in nearly every leg of the COVID-19 vaccine race, but Moderna executives say their companyu2019s mRNA technology gives it an advantage.
Japan Times
JAPAN / Explainer
Oct 20, 2021
Oral drug molnupiravir seen as 'trump card' in Japan's battle against COVID-19
The treatment developed by Merck could receive fast-track approval by the end of the year, and other oral drugs to fight the coronavirus are not far behind.
Japan Times
WORLD / Science & Health
Oct 2, 2021
Merck pill seen as 'huge advance,' raises hope of preventing COVID-19 deaths
An experimental antiviral pill developed by Merck & Co. could halve the chances of dying or being hospitalized for those most at risk of contracting severe COVID-19.
Japan Times
WORLD
Apr 11, 2021
South African variant can 'break through' Pfizer vaccine, Israeli study says
The study suggests the vaccine is less effective against the South African variant, compared with the original coronavirus and a variant first identified in Britain.
Japan Times
WORLD / Science & Health
Mar 20, 2021
Scientists probe new theories on whether AstraZeneca shot linked to blood clots
Scientists are exploring several possibilities that might explain at least 18 reports of extremely rare blood clots in the brain that occurred in individuals in the days and weeks after receiving the AstraZeneca COVID-19 vaccine.
Japan Times
COMMENTARY / World
Sep 11, 2020
Traders are getting smarter about the vaccine race
Investors watching the COVID-19 vaccine development process could be forgiven for thinking it's not so hard. The effort has moved extraordinarily quickly so far, and with few hiccups.
JAPAN / Crime & Legal
Jan 27, 2019
Threatening letters possibly containing toxic materials and demanding money sent to Japanese firms
Nine firms, including drugmakers and a newspaper publisher, have received threatening letters demanding money and containing a white powdery substance believed to be highly poisonous cyanide.
Japan Times
BUSINESS / Companies
Jan 22, 2019
Japan drugmaker Takeda mulls sale of $3 billion in emerging-market assets
Takeda Pharmaceutical Co. is considering a sale of some emerging-market drugs as it expands a push to cut debt after buying Shire PLC for $62 billion, according to sources.
Japan Times
BUSINESS / Companies
Jan 9, 2019
Takeda's CEO says it needs to sell assets quickly to cut debt
The sooner, the better.
Japan Times
BUSINESS / Companies
Jan 8, 2019
Takeda completes buyout of Shire to become top 10 global pharmaceutical firm
Takeda Pharmaceutical Co. said Tuesday it has completed the acquisition of Irish drugmaker Shire PLC and made it a wholly owned subsidiary, becoming a global top 10 pharmaceutical company in terms of sales.
Japan Times
BUSINESS / Companies / ANALYSIS
Dec 6, 2018
Takeda downgrade looms after shareholders approve Shire deal
Takeda Pharmaceutical Co. shareholders' approval of the $62 billion (about ¥7 trillion) acquisition of Shire PLC is good news for its bosses' ambitions to build a global drug giant — but bad news for its credit ratings.
Japan Times
BUSINESS / Companies
Oct 29, 2018
Takeda may sell some European over-the-counter assets as it seeks to slash debt
Takeda Pharmaceutical Co. is considering a sale of assets from its over-the-counter business in Europe, as the drugmaker pursues ways to cut debt after its $62 billion takeover of Shire PLC, people familiar with the matter said.
Japan Times
BUSINESS / Companies / ANALYSIS
Apr 26, 2018
Shire bid marks Takeda's latest and biggest push for global status
Takeda Pharmaceutical Co. Ltd..'s $64 billion bid for London-listed rare-disease specialist Shire PLC bolsters its credentials as Japan's most outward-facing drugs firm, a mold-breaking image that has been more than a decade in the making.
BUSINESS / Companies
Apr 21, 2018
Japanese drugmaker Takeda adds more cash to Shire bid, sending offer past $60 billion
Takeda Pharmaceutical Co. sweetened its offer for drugmaker Shire PLC to more than $60 billion after three prior bids were rejected, wooing investors in the U.S. company with a higher cash component.

Longform

A statue of "Dragon Ball" character Goku stands outside the offices of Bandai Namco in Tokyo. The figure is now as recognizable as such characters as Mickey Mouse and Spider-Man.
Akira Toriyama's gift to the world